Investigating how quinolinate affects immune suppression in glioblastoma
Official title: Quinolinate-induced immune suppression in glioblastoma
Funded at William Beaumont Hospital Research Inst · NIH-10906150 · Data updated 2026-11-12
This study is looking at how a substance called quinolinate affects certain immune cells in the brain that can make it harder for the body to fight glioblastoma, a tough type of brain cancer, with the hope of finding new treatments that could help patients feel better and improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | William Beaumont Hospital Research Inst NIH-funded |
| Lab location | 1 site (Royal Oak, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $368,600 |
| NIH project number | 5R01NS129744-02 |
| Project ID | NIH-10906150 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with glioblastoma who may benefit from novel immunotherapy approaches.
✕Less likely to help
Patients with other types of cancer or those not diagnosed with glioblastoma may not receive any benefit from this research.
What this research studies
This research explores the role of quinolinate, a byproduct of tryptophan metabolism, in glioblastoma, a highly aggressive brain cancer. The study focuses on how quinolinate influences tumor-associated macrophages, which are immune cells that can suppress the body's ability to fight tumors. By understanding the mechanisms of quinolinate's effect on these macrophages, the research aims to develop new therapeutic strategies that could enhance the immune response against glioblastoma. Patients may benefit from potential new treatments that target this metabolic pathway to improve outcomes in glioblastoma.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the immune system's ability to combat glioblastoma.
How similar studies have gone: Previous research has shown promise in targeting immune suppression in other cancers, but this specific approach in glioblastoma is relatively novel.
Where this research is happening
-
William Beaumont Hospital Research Inst
Royal Oak, United States Active
Researchers
- Principal investigator: Chinnaiyan, Prakash — William Beaumont Hospital Research Inst
- Study coordinator: Chinnaiyan, Prakash
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.